Metallothioneins (MTs) are cysteine-rich proteins with a molecular weight of approximately 6000 Da having specific binding capacity for metal ions of group II; they make up the majority of intracellular protein thiols. They are involved in metal detoxification and in the protection of cells against chemical and radiation-induced damage. The MT-1 and MT-2 isoforms, which are ubiquitously expressed in all eukaryotes, were identified almost four decades ago (1). Later, two other isoforms, MT-3 and MT-4, were identified in mammals. MT-3 was initially detected in the brain of patients with Alzheimer's disease (2); it proved able to inhibit neuronal cell growth in culture (3) and was predominantly expressed in glutaminergic brain neurons (4). MT-4 is expressed in the stratified squamous skin epithelium, tongue and intestinal lining, and appears to play an important role in cell differentiation in these tissues (5). MTs have two globular metalbinding domains, α (in the C-terminal region) and β (in the N-terminal region), which are conserved in all four isoforms (6, 7). MT-3 contains an additional C-terminal hexapeptide and proline residues at positions 7 and 9 that may be responsible for its growth inhibitory effect on neuronal cells in culture (8). MT-3 shows limited tissue distribution, is not induced by metals, has neuronal growth inhibitory activity, and sequesters Zn more effectively under Zn-depleted conditions. Recent findings revealed the participation of MT-3 in the development of specific cancer types. The structures of all four isoforms are highly conserved at the amino acid and nucleotide levels among higher eukaryotes, suggesting that these proteins perform important biological functions.
ecules are thermodynamically stable, they are kinetically labile and are exchanged within the same as well as among different molecules or can be donated to other metalloproteins in the presence of glutathione (GSH) (11) .
There are two forms of MT protein, the metal-bound and metal-free (apo-MT) forms. Apo-MT is usually only transiently expressed in non-neoplastic cells under Zndeficient conditions. However, in a study of solid and/or ascitic tumors from mice and rats persistently elevated levels of apo-MT were detected in a number of tumors without any overt evidence of Zn deficiency (12) .
The N-terminal regions of naturally occurring MTs are blocked by acetylation. It has also been reported that both acetylated and nonacetylated forms of MTs are pres-ent in similar amounts in the liver after heavy metalmediated or post-partial hepatectomy induction of MT synthesis (13) . Acetylation of MT protein is probably not essential for its export, as both acetylated and nonacetylated forms have been detected at comparable levels in the plasma of newborn rats.
Although not all primary functions of the MTs have been defined with certainty, these proteins participate in different biochemical reactions occurring in vivo by virtue of their high cysteine content.
METALLOTHIONEINS AND TOXICITY
MTs have an important function in heavy metal metabolism and detoxification and in the management of various forms of cellular stress.
Metal ion homeostasis and detoxification
MTs were initially considered as the mediators of cellular detoxification of metals such as Cd, Hg, Cu and Ag because of their ability to bind heavy metals (10, 11) . By binding biologically essential metals such as Zn and Cu, MTs act as a reservoir for these metals, thus facilitating the reversible transfer of these ions to cellular macromolecules. Many cellular proteins, enzymes, DNA and RNA polymerases and transcription factors require Zn for their biological activity, so MTs control their function by acting either as Zn-donor (MT) or as Zn-acceptor (apo-MT). Apo-MT is known to inactivate the DNA binding capacity of Zn-finger transcription factors in vitro (14) , whereas Zn-MT restores their activity. This reversible activation of transcription factors by MTs is specific for Znfinger proteins (15) . It has also been shown that apo-MTs may activate certain metalloenzymes by abstracting the metal ions bound to a noncatalytic inhibitory site (16) . Overexpression of the apo-MT may lead to chelation of these intracellular Zn ions, inducing inactivation of Zndependent DNA binding proteins (17) .
MTs seem to act early in a biological signaling cas-cade, triggering metal-dependent biochemical and cellular responses. The ratio of MT to apo-MT can regulate Zn homeostasis in response to nitric oxide (NO) signaling events (18) . On the other hand, uncontrolled release of metals by excessive oxidative stress may contribute to metal toxicity (19) . The transfer of metal ions from MT to metalloproteins is facilitated by the presence of redox couples such as GSH and glutathione disulfide (GSSG) (11, 20) . GSH and MT represent two of the most important molecules in the intracellular handling of Cu. Cu sequestering is of vital importance for cell protection, as this element catalyzes the generation of free radicals and/or directly interacts with essential biomolecules. It has been reported that chronic exposure to metals is accompanied by changes in GSH and MT metabolism, leading cells to undergo lytic damage induced by oxidative stress (21) . The role of MTs in Cu homeostasis was also demonstrated in a mouse model for Menkes disease (22) . Deletion of MT-1 and MT-2 genes in these mice proved to be lethal. These studies with MT-null mice demonstrated that MTs are essential for the protection of cells from the adverse effects of metal imbalance under extreme conditions, suggesting also that alternative mechanism(s) may be operative to maintain Zn and Cu homeostasis under normal physiological conditions.
Free radical scavengers
Due to their high cysteine content, MTs can function as potent scavengers of reactive oxygen species, such as hydrogen peroxide (H 2 O 2 ), superoxide (O 2 -), hydroxyl (OH) and NO radicals, protecting cellular macromolecules from these highly reactive compounds that are constantly generated in vivo by various metabolic processes. Mechanisms underlying this function may include direct free radical interception, complexation of redox-sensitive transition metals, alteration of Zn homeostasis or interaction with GSH. MT has a protective effect against the cytotoxic and DNA damaging action of NO. At inflammatory sites, some of the stimuli that induce MT expression also cause induction of NO synthase, resulting in NO production that is scavenged by MT with a concomitant release of Zn. This Zn release is able to suppress further expression and activity of NO synthase, providing evidence that MT is an anti-inflammatory agent (23) . In skin disorders the antioxidant and anti-inflammatory role of Zn has been established through induction of MT synthesis, which protects against free radicals (24) .
DNA protection by MTs from ultraviolet (UV) lightinduced damage also suggests that these proteins scavenge free radicals generated by UV radiation (25) . The function of MTs as antioxidants in vivo was first demonstrated by experiments in yeast. Cu,Zn superoxide dismutase (Sod1) plays an important role in protecting cells from oxygen toxicity (26) . Disruption of the Sod1 gene in Saccharomyces cerevisiae cells sensitive to oxidative stress led to various growth defects and inability for growth on agar containing the respiratory carbon source lactate (26) . These abnormalities could be reversed by overexpressing yeast Cu-MT or monkey MT-1 in Sod1 -/cells. Although yeast Cu-MT and mammalian MT-1 have no structural homology, they can functionally complement each other. These data clearly demonstrated that yeast and mammalian MTs play a direct role in the cellular defense against oxidative stress, acting as antioxidants. The activity of MTs as free radical scavengers in mammalian systems was first demonstrated in MT-1-and MT-2-null embryonic stem cells that are highly sensitive to free radical generators such as t-butyl hydroperoxide, t-butyl hydroquinone, and the redox cycler paraquat (27) . In contrast, MT-1 overexpressing cells were resistant to these agents (28, 29) . The role of MT as a scavenger of free radicals in vivo was demonstrated specifically in the heart of mice overexpressing human MT-2A (30) . MT overexpression after direct MT gene transfer in cultured cells decreased the cytotoxicity by partially reducing reactive oxygen and nitrogen species and markedly attenuated intracellular oxidation of reporter molecules including dichlorofluorescein and cis-parinaric acid. Conversely, in cells derived from mice lacking both functional MT-1 and MT-2 genes, enhanced intracellular oxidation has been observed. GSH levels were unaffected in MT-null cells with respect to wild-type, suggesting that the antioxidant MT function is independent of GSH. There is no correlation between MT and GSH levels, demonstrating the autonomous regulation of MT in intracellular thiol pools. This may be important for anticancer chemotherapies since MT overexpression occurs in human tumor cells with acquired drug resistance. Thus, MT is a stressinducible protein with antioxidant attributes that may participate independently of or in conjunction with GSH to protect cells against injurious agents (31) (32) (33) (34) .
METALLOTHIONEINS AND CANCER
Several lines of evidence suggest a role for MTs in cancer development, treatment resistance and prognosis. The induction of MT synthesis by cytokines, hormones and other cytotoxic agents is indicative of its involvement in cell proliferation and differentiation as well as in cellular defense mechanisms. Studies have reported immunohistochemical MT expression in various human tumors, associated either with processes related to carcinogenesis or with resistance against radiation and chemotherapeutic agents (35) . Using cDNA microarray technology, the MT gene has recently been identified as a candidate chemoresistance-related gene in gastric cancer (36) .
Zn-dependent proteins involved in DNA repair and cell-cycle control represent sensitive targets for some toxic metal compounds. Relevant mechanisms of inhibition appear to be the displacement of Zn by other transition metals as well as redox reactions leading to thiol/disulfide interchange (37) . DNA is permanently damaged by endogenous and environmental factors. Functional processing of DNA lesions is an important prerequisite for maintaining genomic integrity (38) . Its inactivation by metal compounds may therefore constitute an important mechanism of metal-related carcinogenicity (38) .
The p53 tumor suppressor protein has a DNA binding domain stabilized by a Zn ion, which is necessary for a functionally active configuration of wild-type p53 (39) (40) (41) (42) (43) . Chelation of Zn disrupts the architecture of the p53 DNA binding domain, inducing the protein to adopt an immunological phenotype identical to that of many mutant p53 forms (44) . Apo-MT also has the potential to remove Zn from p53 and inactivate it similarly to other Zn chelators (41) . Micro-injection of apo-MT into living cells has been shown to be capable of removing Zn from Znfinger DNA binding proteins, Sp-1, and transcription factor IIIA (14, 15) . Persistent apo-MT overexpression in tumor cells, if present, may promote their accelerated growth and increased survival through induction of a p53-null state. The recently observed capacity of MT-specific anti-sense oligonucleotides to cause cell growth arrest and to induce apoptosis in ductal breast carcinoma cells (45) lends support to this hypothesis, as does the lower p53 mutation frequency observed in breast cancer cases showing MT overexpression. Increased MT gene expression in breast cancer has been associated with metastasis and poor prognosis and MT overexpression potentiates the growth of MCF7 cells, whereas its downregulation elicits antiproliferative effects (45) .
The MT-1 gene is silenced by methylation of CpG islands in mouse lymphosarcoma P1798 cells but not in the thymus, the cell type from which the tumor was derived. Bisulfite genomic sequencing revealed that all 21 CpG dinucleotides present within -216bp to +1bp with respect to the transcription start site were methylated in the tumor cell line, but none was methylated in the thymus. The lymphosarcoma cells induced MT-1 in response to heavy metals, only after demethylation with 5-azacytidine (5-AzaC). The electrophoretic mobility shift assay, which uses specific oligonucleotide probes, showed that the key transcription factors regulating the MT-1 gene (e.g. MTF-1, Sp1 and MLTF/USF) were active in P1798 cells. In vivo footprinting of the proximal promoter region showed that none of the metal regulatory elements (MREs) or MLTF/USF were occupied in response to heavy metals. Demethylation of the lymphosarcoma cells with 5-AzaC resulted in constitutive footprinting at MLTF/ARE, and Zn-inducible footprinting at MRE-c, MRE-d and MRE-e sites. Demethylation of only 10-20% of the CpG islands was sufficient to render the gene inducible by Cd and Zn. MT-1 induction persisted in cancer cells for several generations even after withdrawal of 5-AzaC from the culture medium (46) . Suppression of the MT-1 gene and probably other genes in a solid tumor by promoter methylation has been reported; this provides potential molecular mechanisms for the altered methylation profile of the genes in this tumor, participating subsequently in cancer development (47) .
MT and cell proliferation or apoptosis
MT expression in tumor tissues has been mainly correlated with the proliferative capacity or apoptosis of tumor cells (45, 48) . MT expression was cell-cycle dependent and could be used as a marker of cell proliferation in certain tumor types, presenting preferential expression in cells in the S-phase (49) . It is also known that perinuclear MT mRNA localization is important for the protective function of MT against DNA damage and apoptosis induced by external stress (50) . MT suppressed hypoxia/reoxygenation-induced cardiomyocyte apoptosis at least in part through inhibition of cytochrome c-mediated caspase-3 activation (51). A muscle cell line that highly expressed MT was differentiated slowly, presenting a low apoptosis rate compared with an MT-negative one (52) . In response to stress and/or environmental stimuli, MT was rapidly and transiently induced, constituting a cellular protection mechanism able to neutralize external apoptotic signals (53) . MTs are overexpressed in prostate and ovarian cancers, conferring resistance to radiation and cytotoxic anticancer drugs (54) . In the human prostate cancer cell line PC-3 and the ovarian cancer cell line SKOV-3, the inhibition of MT-2 by sequencespecific ribozymes (Rzs) targeting MT resulted in a dosedependent attenuation of MT-2A transcripts and a dramatic reduction of the cell number in these cell lines, probably due to apoptosis (54) . The Rz-induced loss of MT-2A mRNA-associated cell death in these cancer cell lines was accompanied by dose-dependent downregulation of the proto-oncogene c-myc and the apoptosis inhibitory mediator bcl-2, suggesting that these signaling pathways are involved in this process. MT-2A proved to be an important cell-survival or anti-apoptotic factor for prostate and ovarian cancer cells; its downregulation via transgenic expression of a sequence-specific Rz therefore appears to be a feasible target for cancer therapy (54) .
MT and drug resistance
One of the most important problems in cancer chemotherapy is acquired drug resistance, and a mechanism that supposedly contributes to this phenomenon is the sequestration of alkylating agents by MT in vivo. However, data obtained from multiple sources indicate that the resistance to chemotherapy exhibited by different human tumor types cannot be explained by a single mechanism.
Rabbit liver MT-2 was shown to form covalent bonds with the anticancer agent melphalan, supporting the hy-pothesis that covalent sequestration by MT constituted one mechanism for the acquired cross-resistance to therapeutic alkylating agents of cancer patients (55) . Human bladder tumor T24 cells exposed to chlorambucil and melphalan were examined for MT expression and for its ability to adduct chemotherapeutic agents. MT-2A made up 56% of the MT isoforms in T24-induced cells. Drug adducts of MT-2A were isolated and characterized by HPLC and electrospray ionization mass spectrometry, and one to four drug equivalents were found to be covalently adducted. The major binding sites on MT were located in the C-terminal domain, consistent with previous in vitro studies (56) . Resistance to cisplatin is the major obstacle to its clinical effectiveness. Multiple mechanisms may be involved in cisplatin resistance including reduced accumulation as the most common one as well as elevated levels of GSH and MT, enhanced DNA repair, alterations of oncogene expression and signal transduction pathways involved in apoptosis (57) . The role of MT in the chemosensitivity of transplanted tumors in mice was recently examined. The antitumor activities of various chemotherapeutic agents such as cisplatin, adriamycin, bleomycin, peplomycin, cyclophosphamide and melphalan were significantly suppressed when the tumor MT concentration was increased to only twice the control level. By contrast, the antitumor activities of mitomycin C, 5-fluorouracil and vinblastine were hardly affected by increased MT concentrations in tumor bearing mice. Treatment of patients with certain antitumor drugs might therefore result in the resistance of their tumors to these drugs (58) . Moreover, all antitumor drugs examined increased the MT concentration in transplanted tumors at a level that was high enough to suppress their antitumor activity (58) . Cisplatin, one of the most active agents against various malignancies, presents resistance associated with MT overexpression. Using a virus-free system (liposomes), it was attempted to express the suicide gene thymidine kinase (TK), driven by the promoter of the human MT-2A gene using the pMT-TK plasmid, on a model of cisplatin-resistant human ovarian carcinoma cells. The cisplatin-resistant cells presented increased MT mRNA expression compared to parental cells, suggesting that pMT-TK gene therapy may provide an alternative treatment for cisplatin-refractory ovarian tumors (59) . Pt (IV) complexes induce the biosynthesis of MT in rabbits (33) and react with Cd,Zn-MT in vitro, developing drug resistance (32) , so MT is involved in the metabolism and use of Pt(IV) complexes as antitumor agents (33) . No evidence for altered MT isoform profiles in drug-resistant cells that overexpress MT was found. Recent findings suggested that subcellular MT location may dictate functionality and MT may help to determine the threshold for apoptosis. In addition, modulation of MT expression might provide a strategy for altering cellular resistance to chemotherapeutic compounds and apoptosis (60) .
MT and radiation resistance
The protective effect of MT in radiation injury has been documented both in vivo and in cells after pre-induction of MT synthesis by various agents. This radioprotective effect may be due either to MT itself or to other cellular factors modulated by MT action (61) . Repeated doses of radiation proved to be more effective than a single large dose in inducing MT synthesis. It is unclear whether radiation itself can induce MT synthesis or induction of MT occurs secondarily to the formation of free radicals or release of cytokines. MT mRNA and protein expression were found to be induced by exposure to ionizing or UV radiation of cells in vitro or of tissues in vivo. In most of the animal and in vitro studies high doses of ionizing radiation were used to induce MT. It is therefore difficult to extrapolate these results to low levels of repeated radiation exposure in humans. Induced MT synthesis is considered one of the mechanisms involved in the adaptive response to low-dose radiation exposure. In normal cells MT might provide protective effects against radiation-induced genotoxicity and cytotoxicity, although its presence in tumor cells could result in drug and radiation resistance (61) . MT with radical-scavenging activity might contribute, at least in part, to photoprotection against UVB-induced oxidative damage in mammalian skin (62, 63) . The skin of MT-null mice developed a larger number of sunburn cells and apoptotic cells than skin of normal mice, indicating that the skin of MT-null mice is readily injured by UVB irradiation and providing direct evidence for the dermoprotective effects of MT (64) . MT levels induced in tumor cells by X irradiation were elevated not only after a single but also after repeated exposures. Several studies have shown that MT is one of the important cellular factors in resistance to ionizing radiation (65) . The role of MT in radiation exposure may be important not only in radioprotection but also in the treatment of certain cancer types with drugs and radiation. The presence of MT may be one of several factors involved in the radioresistance of tumor tissue and the adaptive response to low-dose ionizing radiation.
CONCLUSIONS
It is becoming evident that MT plays a role in tumor cell pathobiology, at least in certain tumors, as many tumors express high levels of MT while others are essentially devoid of this protein. The accumulated knowledge on MT expression in relation to histopathological parameters, drug resistance, patient survival and prognosis is contradictory between different cancer types. This is mainly due to the methods applied and to the use of antibodies that are unable to distinguish specific MT isoforms, or metal-bound and metal-free (apo-MT) forms of the protein. Unlike the MT-1 and MT-2 genes, the MT-3 and MT-4 genes are expressed in specific tissues and cell types. In most studies where immunohistochemistry was used, MT expression was revealed with antibodies against a common epitope of MT-1 and MT-2 that was unable to detect overexpression due to other isoforms or subtypes. It is therefore possible that the tumor prognosis-associated differences noted are related to the isoform and metal status of MT overexpression characteristic of each tumor type. It is also evident that MT expression was decreased in cancer cells obtained from tissues mainly implicated in metal ion homeostasis such as liver, kidney, gastrointestinal and urinary tract. In such tissues not only the specific MT isoform expression but also the lack of its expression could participate in the carcinogenic transformation. The functional significance of MT expression in human tumors remains to be determined, in relation to specific MT isoforms and/or apo-MT, which are capable of differentially influencing the growth and survival pattern of tumor cells in specific tissue types.
The purpose of the expression of different MT isoforms in certain tissues is not clearly evident. It would be challenging to identify and characterize the tissue-specific factors responsible for the expression of these genes. It is conceivable that the tissue-specific expression of MTs is governed by the modification of chromatin structure. The role of different transcription factors and different chromatin modifying factors in the dynamics of MT chromatin structure in vivo and in vitro needs to be explored. Analysis of the expression of different MT isoforms in human tumors in relation to their metal ion composition, cellular antioxidant defense mechanisms, and genetic alterations in specific genes related to MT, using appropriately sensitive and discriminant methods, should elucidate the participation of this group of proteins in toxicity and carcinogenesis. Further studies on differential MT isoform and isotype expression in different tumor types could clarify the clinical significance of this family of proteins.
